Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) just unveiled an update.
Lepu Biopharma Co., Ltd. successfully conducted its first extraordinary general meeting for 2025, presided over by chairman Dr. Pu Zhongjie. During this meeting, all proposed resolutions, including the approval of a framework agreement with Lepu Medical Technology for CDMO services and the appointment of Ernst & Young as auditors, were passed with overwhelming shareholder support. These developments signify a strategic collaboration and financial oversight enhancement, potentially strengthening the company’s operational capabilities and market positioning.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. is a joint stock company incorporated in the People’s Republic of China. It operates in the biopharmaceutical industry, focusing on developing innovative medical treatments and technologies. The company collaborates with entities like Lepu Medical Technology to enhance its service offerings, targeting a diverse market within the healthcare sector.
YTD Price Performance: -4.20%
Average Trading Volume: 5,642,659
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$4.29B
For detailed information about 2157 stock, go to TipRanks’ Stock Analysis page.